natgillin/translations-raw huggingface dataset:
The composition of claim 1 or 2, wherein G is covalently bound to L via its tertiary nitrogen or via an amino, hydroxyl or carboxyl functional group of one of its substituents. 
[image] pri tome je q = 1-6, [image] i G je derivat karboksipiridina koji je vezan preko amidne veze za G2, pri tome je G kovalentno vezan za L preko njegovog tercijarnog dušika i pri čemu je G2 aminokiselina odabrana iz skupine koja se sastoji od standardne aminokiseline, nestandardne aminokiseline i sintetske aminokiseline.
Intermediate (2) 2,4-Dichloro-3-bromomethyl-benzenesulfonyl chloride ml of chlorosulfonic acid were dropwise added with 4.8 ml of 2,6-dichlorotoluene in two hours, under magnetic stirring at room temperature. 
Međuprodukt (2) 2,4-Diklor-3-bromometil-benzensulfonil klorid 10 mL klorsulfonske kiseline je dokapano u 4.8 mL 2,6-diklortoluena kroz dva sata uz magnetsko miješanje pri sobnoj temperaturi.
The isolated binding molecule of claim 1, wherein the binding molecule is human. 
Molekula za vezanje u skladu s patentnim zahtjevom 1, naznačena time, da je molekula za vezanje ljudska molekula.
Floor panel according to any of the claims 1 to 6, characterized in that the locking element (12) is formed by coextrusion. 
Podni panel prema patentnom zahtjevu 1 do 6, naznačen time što je element za blokiranje (12) napravljen koekstruzijom.
represents a C1-6 alkyl group, a C1-6 haloalkyl group, a C2-6 alkenyl group, a C3-8 cycloalkyl group, a hydroxyl group, a C1-6 alkoxy group, or a halogeno group, R5 represents a C1-6 alkyl group, a C1-6 haloalkyl group, a C6-10 aryl C1-6 alkyl group, a C3-8 cycloalkyl group, a C6-10 aryl group, a C1-7 acyl group, a C1-6 alkoxycarbonyl group, a C1-6 alkoxy group, an amino group, a mono C1-6 alkylamino group, di C1-6 alkylamino group, a C1-6 alkoxycarbonylamino group, a C1-6 alkylthio group, a C1-6 alkylsulfonyl group, a halogeno group, a cyano group or a nitro group, Y and Z are both carbon atom, D is an aromatic ring which includes both Y and Z, and X represents an oxygen atom. 
predstavlja skupinu C1-6 alkil, skupinu C1-6 haloalkil, skupinu C2-6 alkenil, skupinu C3-8 cikloalkil, skupinu hidroksil, skupinu C1-6 alkoksi, ili halogenu skupinu, predstavlja skupinu C1-6 alkil, skupinu C1-6 haloalkil, skupinu C6-10 aril C1-6 alkil, skupinu C3-8 cikloalkil, skupinu C6-10 aril, skupinu C1-7 acil, skupinu C1-6 alkoksikarbonil, skupinu C1-6 alkoksi, amino skupinu, skupinu mono C1-6 alkilamino, skupinu di C1-6 alkilamino, skupinu C1-6 alkoksikarbonilamino, skupinu C1-6 alkiltio, skupinu C1-6 alkilsulfonil, halogenu skupinu, cijano skupinu ili nitro skupinu, Y i Z su oba ugljikov atom, D je aromatski prsten koji sadrži oba Y i Z, i X predstavlja kisikov atom.
a polyalkylene-modified polymethylsiloxane non-ionic surface active agent, 
polialkilen-modificirani polimetilsiloksan neionski površinski aktivni agens,
In another example, the third user marking cell may be detected based at least in part upon at least both of: (a) the displacement vector of the detected first user marking cell; and (b) the displacement vector of the detected second user marking cell. 
Postupak u skladu s patentnim zahtjevom 2, naznačen time što se treću ćeliju za korisničku oznaku detektira na temelju u najmanju ruku dijelom: (a) vektora pomaka detektirane prve ćelije za korisničku oznaku; i/ili (b) vektora pomaka detektirane druge ćelije za korisničku oznaku.
A pharmaceutical composition comprising a compound of Formula (Ia): or a pharmaceutically acceptable salt thereof, and hypertonic saline. 
Farmaceutski sastav prema zahtjevu 3, koji sadrži spoj formule (Ia) [image] ili njegovu farmaceutski prihvatljivu sol i hipertoničnu otopinu.
hydrogenating compound (15), or salt thereof, to obtain a compound according to formula (16), or salt thereof, and 
(15) pri čemu R1 je vodikova ili dušikova zaštitna skupina, kako bi se dobio spoj u skladu s formulom (16).
The anti-CD40 antibody or antigen-binding fragment of claim 1 or the use of claim 2, wherein said antigen-binding fragment of said anti-CD40 antibody is selected from the group consisting of an Fab fragment, an F(ab')2 fragment, an Fv fragment, and a single-chain Fv fragment. 
Antigen-vezujući fragment prema zahtjevu 8, naznačen time da je navedeni fragment odabran iz grupe koja se sastoji od Fab fragmenta, F(ab’)2 fragmenta, Fv fragmenta, i jednolančanog Fv fragmenta.
In a further aspect the invention thus provides a pharmaceutical composition comprising a pharmaceutically acceptable salt of an amphiphilic photosensitizing agent as herein described, together with a therapeutic agent. 
Farmaceutski sastav koji sadrži farmaceutski prihvatljivu sol amfifilnog fotosenzibilizirajućeg agensa kako je definirano u patentnom zahtjevu 1, zajedno s terapijskim agensom, za uporabu u liječenju.
Liquid preparations for oral administration can be in the form of solutions, emulsions, aqueous or oily suspensions, and syrups. 
Tekući pripravci za oralnu primjenu mogu biti u obliku otopina, emulzije, vodenih ili uljnih suspenzija te sirupa.
Method according to claim 6, characterized in that said medium is a serum-free medium, or a serum-free medium supplemented with defined animal-derived components, or an animal-derived component free medium, or a protein-free medium, a protein-free medium supplemented with defined animal-derived components, or a defined protein-free medium, or a chemically defined medium. 
Postupak prema patentnom zahtjevu 8, naznačen time, da spomenuti medij je medij bez seruma, ili medij bez seruma dopunjen definiranim komponentama životinjskog porijekla, ili medij bez komponenti životinjskog porijekla, ili medij bez proteina, ili medij bez proteina dopunjen definiranim komponentama životinjskog porijekla, ili definirani medij bez proteina, ili kemijski definirani medij.
An affinity reagent according to claim 8, wherein the affinity reagent is a fully human or humanised antibody that is capable of inducing antibody-directed cell-mediated cytotoxicity (ADCC). 
Protutijelo za uporabu sukladno bilo kojem od zahtjeva 1 do 4, naznačeno time da je antitijelo potpuno ljudsko ili humanizirano protutijelo koje može inducirati stanično uzrokovanu citotoksičnost usmjerenu protiv protutijela (ADCC).
Levels of formula (II) in simulated Intestinal fluid (ng/mL) Unformulated drug 
[Razina formule (II) u simuliranoj crijevnoj tekućini (ng/mL) Neformulirani lijek
The polypeptide of any preceding claim wherein the first proximal end is within a short repeat. 
Polipeptid u skladu s patentnim zahtjevom 6, naznačen time što je prvi proksimalni kraj unutar ponavljanog dijela VII toksina A.
A product comprising a recombinant human follicle stimulating hormone (FSH) for use in the treatment of infertility in a patient having serum AMH level of < 15 pmol/L, wherein the product is to be administered at a dose of, or equivalent to, 11-13 µg recombinant human FSH per day, together with a GnRH antagonist. 
Proizvod koji sadrži rekombinantni ljudski folikulostimulirajući hormon (FSH) za upotrebu u liječenju neplodnosti kod pacijenta koji ima razinu seruma AMH <15 pmol/L., naznačen time da se proizvod daje u dozi, ili ekvivalentnoj od, 11-13 ug rekombinantnog ljudskog FSH dnevno, zajedno s antagonistom GnRH.
A composition for tablets comprising crystalline apixaban particles having a mean particle size less than 89 µm and a D90 less than 89 µm as measured by laser light scattering, wherein the composition comprises up to 5 mg apixaban, a pharmaceutically acceptable diluent or carrier and a surfactant, wherein the surfactant is present in a concentration of 0.25% to 2% by weight and serves as a wetting aid for apixaban drug substance, wherein the composition is obtainable by a process comprising an air-jet milling process to reduce apixaban particle size to the desired size and dry granulation. 
Tableta ili kapsula koja sadrži farmaceutsku kompoziciju, gdje farmaceutska kompozicija sadrži apiksaban i farmaceutski prihvatljiv razrijeđivač ili nosač, gdje je apiksaban u obliku tvari i kristalnom obliku i pojedinačne tvari apiksabana, bilo da tvari postoje zasebno ili u aglomeratu, imaju D90 jednak ili manji od 89 µm kao što je mjereno raspršivanjem laserske svjetlosti.
The pharmaceutical composition for use of any of claims 1-6, wherein said antibody molecule is a humanized antibody molecule, and/or a monospecific antibody or a bispecific antibody molecule. 
Molekula antitijela prema zahtjevu 1, pri čemu je spomenuta molekula antitijela humanizirana molekula antitijela i/ili monospecifična molekula antitijela ili bispecifična molekula antitijela.
Het as a group or part of a group is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms each independently selected from nitrogen, oxygen and sulfur, said heterocyclic ring being optionally condensed with a benzene ring; and Het as a whole being optionally substituted with one, two or three substituents each independently selected from the group consisting of halo, hydroxy, nitro, cyano, carboxyl, C1-6alkyl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkylcarbonyl, amino, mono- or di-C1-6alkylamino, azido, mercapto, polyhaloC1-6alkyl, polyhaloC1-6alkoxy, C3-7cycloalkyl, pyrrolidinyl, piperidinyl, piperazinyl, 4-C1-6alkylpiperazinyl, 4-C1-6alkylcarbonylpiperazinyl, and morpholinyl; wherein the morpholinyl and piperidinyl groups may be optionally substituted with one or with two C1-6alkyl radicals; and 
Het kao skupina ili kao dio skupine je 5- ili 6-člani zasićeni, djelomično nezasićeni ili u cijelosti nezasićeni heterociklički prsten koji sadrži 1 do 4 heteroatoma od kojih je svaki nezavisno odabran iz dušika, kisika i sumpora, pri čemu je navedeni heterociklički prsten proizvoljno kondenziran sa nekim benzenskim prstenom; i pri čemu navedeni het je u cijelosti proizvoljno supstituiran sa jednim, dva ili tri supstituenta od kojih je svaki nezavisno odabran iz skupine koja se sastoji od halo, hidroksi, nitro, cijano, karboksila, Ci.galkila, C,salkoksi, Cy.galkoksiC.. salkila, Ci .salkilkarbonila, amino, mono- ili di-C,.salkilamino, azido, merkapto, polihaloC; salkila, polihaloC.. salkoksi, CagCikloalkila, pirolidinila, piperidinila, piperazinila,
In a further embodiment, the present invention also concerns the above pharmaceutical tablet obtained by compression of the herein described pharmaceutical tablet formulation, wherein the herein described pharmaceutical tablet formulation is subject to roller compaction before compression into tablet. 
Farmaceutska tableta dobivena komprimiranjem farmaceutske formulacije tablete u skladu s bilo kojim zahtjevom 1 do 13, naznačena time, da je farmaceutska formulacija tablete podvrgnuta sabijanju valjkom prije komprimiranja u tabletu.
In a further aspect of the invention the transition metal catalyst is on a suitable support, for example carbon. 
Postupak prema zahtjevu 6 naznačen time da je katalizator od prijelaznog metala na ugljikovoj podlozi.
A pharmaceutical composition comprising the cephalosporin derivative according to claim 5, an in vivo hydrolysable ester thereof, an in vivo hydrolysable phosphate ester thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, diluent, adjuvant, or any combination thereof, as an effective ingredient. 
m o O dH Farmaceutski pripravak naznačen time da kao djelotvorni sastojak sadrži derivat cefalosporina prema bilo kojem od zahtjeva 1-5, njegov hidrat, njegov solvat ili njegovu farmaceutsku sol; te farmaceutski prihvatljiv nosač, razrjeđivač, pomoćno sredstvo, ili bilo koju njihovu kombinaciju.
Method of any one of claims 1 to 7, characterised in that in the feeding stage, the parget with which the extruding machine is fed has a granulometry comprised between 5 and 12 mm. 
Postupak temeljem bilo kojeg zahtjeva 1 do 7, naznačen time da u fazi punjenja, žbuka koja puni ekstruder, ima granulometriju od 5 do 12 mm.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidenebenzonorbornene-5-yl)amide and as component (B) chlorothalonil. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) fluopiram.
The compound of Claim 1, where a is 0, R3 and R5 are hydrogen, and R4 and R6 are fluoro. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da a je 0, R3 i R5 su vodik a R4 i R6 su fluoro.
Class II caramels are prepared by heating carbohydrates with or without acids or bases in the presence of sulphite compounds, but in the absence of ammonium compounds. 
Karamele klase II se dobivaju zagrijavanjem ugljikohidrata sa ili bez kiselina ili baza, u prisutnosti sulfitnih spojeva, ali u odsutnosti amonijevih spojeva.
The method of claim 1, further comprising: providing the surgeon feedback associated with the location and orientation of the IOL within the eye; and 
pribavljanje povratnih podataka kirurgu povezanih sa mjestom i orijentacijom IOL-a unutar oka; i uporaba navođenja položaja za provjeru (80) pozicioniranja IOL-a unutar oka.
The method of claim 8, wherein the fixing is provided by attaching a securing element (20) to the entry ends holding them together and sewing across the hood channel (38) proximate left and right ends of the securing element (20) defining a pocket that restrains the securing element (20) against lengthwise movement. 
Postupak prema patentnom zahtjevu 8, pri čemu se pričvršćivanje izvodi namještanjem sigurnosnog elementa (20) na ulazne krajeve koji ih drže zajedno 1 ušivanje preko kanala (38) kapuljače bližeg lijevom kraju 1 desnom kraju pričvrsnog elementa (20) koji definira džep koji ograničava sigurnosni element (20) protiv pomjeranja po dužini.
A compound selected from compounds having the following formula: wherein a, b and c respectively denote, independently from each other, a single bond or a double bond, with the proviso that at least one of a, b and c represents a double bond, and with the proviso that if a is single bond and b is double bond R2 is not H; 
PATENTNI ZAHTJEVI Spoj izabran između spojeva koji imaju sljedeću formulu: gdje a, bi c odgovarajuće označavaju, nezavisno jedan od drugoga, jednostruku vezu ili dvostruku vezu, uz uvjet da barem jedan od a, b i c predstavlja dvostruku vezu, i uz uvjet da ako je a jednostruka veza i b je dvostruka veza, tada R2 nije H;
The method according to claim 1, wherein the column contains column packing material that has an average particle size in the range of 30-180 um. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što materijal za pakiranje stupca ima prosječnu veličinu čestica u rasponu od 30-180 µm.
A PRLR neutralizing antibody or antigen-binding fragment as a medicament for the treatment and/or prevention of endometriosis and adenomyosis (endometriosis interna). A PRLR neutralizing antibody or antigen-binding fragment as a medicament for female contraception. 
Antitijelo ili fragment koji veže antigen prema bilo kojem od zahtjeva 1 do 4 naznačeno time da je za uporabu kao lijek za liječenje i/ili prevenciju endometrioze i adenomioze (endometriosis interna).
determination of a set of residual data items by comparison of data items relating to the current partition and the predicted partition, the residual data items being associated respectively with various digital information items which are intended to undergo an entropy encoding, generation of a signal containing the encoded information items. 
- < određivanje (C6) skupa preostalih stavki podataka usporedbom stavki podataka koje se odnose na trenutnu particiju i predviđenu particiju, te su navedene preostale stavke podataka povezane s odgovarajućim različitim digitalnim informacijama koje su namijenjene podvrgavanju entropijskom kodiranju, te je skup preostalih stavki podataka blok preostalih stavki podataka,
In one embodiment, provided is Compound_4 that is a 19-mer double-stranded nucleic acid molecule wherein sense strand is SEQ ID NO:101 and includes 2′OMe modified ribonucleotides in positions 4, 11, 13, and 17; a 2′-5′-ribonucleotide in position 9; a C3OH non-nucleotide moiety covalently attached at the 3′-terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5′-terminus; and the antisense strand is SEQ ID NO:168 and includes 2′OMe modified ribonucleotides in positions 1, 4, 8, 11 and 15; a 2′-5′-ribonucleotide in position 6; a C3Pi-C3OH overhang covalently attached at the 3′-terminus. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačen time što smisleni lanac sadrži SEQ ID NO:101, a protusmisleni lanac sadrži SEQ ID NO:168; gdje smisleni lanac dodatno sadrži 2'-O-metilom modificirane ribonukleotide na položajima 4, 11, 13,1 17; 2'-5'-ribonukleotid na položaju 9; C3OH nenukleotidni HR P20181440 T1 ostatak kovalentno vezan na 3'-kraju; i invertirani nebazni deoksiribonukleotidni ostatak kovalentno vezan na 5'- kraju; i gdje protusmisleni lanac dodatno sadrži 2'-O-metilom modificirane ribonukleotide na položajima 1, 4, 8, 11115; 2'-5'-ribonukleotid na položaju 6; i C3Pi-C30H ostatak kovalentno vezan na 3'-kraju.
The method of any one of items 1 to 6, wherein the pH of at least one precipitation step is maintained for the entire precipitation step by continuous adjustment of the pH. 
(i) stavljanje u doticaj prvog obogaćenog sastava ciljanog proteina izvedenog iz plazme s kromatografskom smolom, pod uvjetima koji su pogodni za vezanje najmanje jedne nečistoće; 1
The first interior guiding passage of the flushing unit may be arranged coextendingly inside the inner tube, so that this passage is connected to the interior guiding passage of the tubular member when connecting the flushing unit thereto. 
Prvi unutarnji prolaz za vođenje jedinice za ispiranje može biti postavljen tako da se isto tako prostire u unutarnjoj cijevi, pa da se taj prolaz spoji na unutarnji prolaz za vođenje cijevnog elementa, kada se jedinica za ispiranje spoji na njega.
Many of the compounds represented by formula (I) are capable of forming acid addition salts, particularly pharmaceutically acceptable acid addition salts. 
Mnogi spojevi prikazani s formulom (I) mogu tvoriti kiselinske adicijske soli, posebno farmaceutski prihvatljive kiselinske adicijske soli.
No. 5,156,845 describes a dry mouth lozenge comprising anon-cariogenic sweetener such as sorbitol, a gum base and a fluoride, and 
- US 5,156,845 opisuje tablete protiv suhoće usta koje sadrže ne-kariogeni zaslađivač kao stoje sorbitol, gumenu bazu i fluorid, i
A compound of formula (III): wherein: 
Spoj formule (III): naznačen time, da:
After assembly the shell 14 is thermally bonded at bonding spots or bonding areas 1, 2 which are located within the contact path 3. This is illustrated, for example, in Figure 6 as the spot weld 53, where the shell is bonded to the cup body shoulder 32 or the annular outer surface 38 adjacent its lower edge 41. 
Nakon sklapanja ljuska 14 se termički spaja na jednoj točki spajanja ili na više točaka spajanja ili na jednom mjestu spajanja ili na više mjesta spajanja 1,2 koji su prikazani, na primjer, na slici 6 kao mjesto točkastog zavarivanja 53, gdje je ljuska spojena na izbočinu 32 tijela čaše ili na vanjsku prstenastu površinu 38 koja se nalazi uz njezin donji rub 41, to jest na razmaku od oko 5 mm od zavijutka 34.
The process of claim 8, comprising reacting compound (VII) with an organomagnesium halide selected from the group consisting of a C1-8alkylmagnesium halide and a C5-7cycloalkylmagnesium halide; in the presence or absence of a lithium halide selected from the group consisting of lithium chloride, lithium bromide, and lithium iodide; followed by the addition of carbon dioxide gas; in an aprotic organic solvent selected from the group consisting of THF, 2-MeTHF, MTBE, CPME, and toluene; at a temperature of about 0 °C; to yield the corresponding carboxylic acid compound (1c). 
Postupak prema zahtjevu 8, koji obuhvaća reakciju spoja (VII) sa organomagnezijevim halogenidom koji je izabran iz grupe koja se sastoji od C,galkilmagnezijev halogenida i Cs.gcikloalkilmagnezijev halogenida; u prisustvu ili odsustvu litij halogenida koji je izabran iz grupe koja se sastoji od litijevog klorida, litijevog bromida, i litijevog jododa; praćeno dodavanjem plina ugljikovog dioksida; u aprotonskom organskom otapalu koje je izabrano iz grupe koja se sastoji od THF, 2-MeTHF, MTBE, CPME, i toluena; na temperaturi od oko 0 *C; da bi se dobio odgovarajući spoj karboksilne kiseline (1c).
In accordance with some embodiments the dipeptide prodrug element is linked at the N-terminal amine of the peptide or analog described herein, including for example a glucagon related peptide, or osteocalcin, as well as analogs, derivatives and conjugates of the foregoing, wherein the dipeptide prodrug element comprises the structure: 
Farmaceutski pripravak, naznačen time što sadrži peptid ili peptidni analog u skladu s bilo kojim od patentnih zahtjeva 1-10, dimer ili multimer u skladu s patentnim zahtjevom 11, konjugat u skladu s patentnim zahtjevom 12, ili njihovu kombinaciju, kao i farmaceutski prihvatljiv nosač, razrjeđivač ili pomoćnu tvar.
A nitroxyl donor for use in a method of treating pulmonary hypertension, which method comprises administering to a mammal in need thereof an effective amount of the nitroxyl donor, wherein the nitroxyl donor is a compound of formula (III) or a pharmaceutically acceptable salt thereof, wherein: 
Donor nitroksila za primjenu u metodi za liječenje plućne hipertenzije, pri čemu metoda sadrži administriranje kod sisavaca kojima je potrebna efikasna količina donora nitroksila, gdje je donor nitroksila spoj formule (III) Q? R aa |
accelerating movement of the at least one of the shoes toward the other of the shoes, upon release of the spring from the compressed state. 
ubrzavajuće kretanje, s elastičnim elementom (90), barem jedne papučice prema drugoj papučici tijekom ciklusa aktivacije kočnice.
The method of claim 19, wherein administration of cangrelor is discontinued between 1 and 24 hours prior to the invasive procedure. 
Reverzibilni, kratko djelujući inhibitor P2Y,> za uporabu u postupku prema zahtjevu 1, naznačen time da se davanje cangrelora prekida između 1 i 24 sata prije invazivnog postupka.
An intermediate compound which is selected from the group of: and 
15. Intermedijerni spoj koji je izabran iz grupe koju čine:
A recombinant RhCMV or HCMV vector comprising a nucleic acid sequence encoding a heterologous antigen, wherein the heterologous antigen is a human pathogen-specific antigen or a tumor antigen, wherein the vector is replication-deficient and comprises a deletion in the RhCMV Rh110 or HCMV UL82 gene encoding pp71. 
Rekombinantni RhCMV ili HCMV vektor koji sadrži sekvencu nukleinske kiseline koja kodira heterologni antigen, naznačen time što je heterologni antigen ljudski patogen specifičan antigen izoliran iz hepatitis B virusa (HBV), pri čemu vektor uključuje brisanje jednog ili više RhCMV ili HCMV gena koji su esencijalni za ili povećavanje replikacije.
Compounds of formula (X) wherein is 
Spoj formule (1) je ili
A reference signal generation method used by a radio communication apparatus comprising: 
Metoda generiranja referentnog signala za moguću uporabu u Koordiniranom prijenosu i prijemu Više Točaka, CoMP, metoda sadržeći:
in step (e), the filler is microcrystalline cellulose and the disintegrant is sodium starch glycolate; and in step (f), the lubricant is magnesium stearate. 
u koraku (e), punilo je mikrokristalna celuloza i sredstvo za raspadanje je natrijev škrob glikolat; i u koraku (f), sredstvo za povećanje skliskosti je magnezijev stearat.
providing a vaccine featuring the cancer mutation signature obtained in step (a). 
(ab) osiguravanje RNK cjepiva koje sadrži mutacijsku signaturu raka dobivenu u koraku (aa), pri čemu